Technical Analysis for CVM - Cel-Sci Corporation

Grade Last Price % Change Price Change
grade C 6.57 4.45% 0.28
CVM closed up 4.45 percent on Friday, July 19, 2019, on 52 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. The stock rose above its 50 day moving average, improving its intermediate-term outlook by crossing above that important trendline. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Up Up Down
See historical CVM trend table...

Date Alert Name Type % Chg
Crossed Above 50 DMA Bullish 0.00%
Narrow Range Bar Range Contraction 0.00%
NR7 Range Contraction 0.00%
NR7-2 Range Contraction 0.00%
Wide Bands Range Expansion 0.00%
Oversold Stochastic Weakness 0.00%
NR7 Range Contraction 4.45%
Stochastic Reached Oversold Weakness 4.45%
Wide Bands Range Expansion 4.45%
Down 3 Days in a Row Weakness 4.45%

Older signals for CVM ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
CEL-SCI Corporation engages in the research and development of drugs and vaccines. The company's principal product, Multikine, is under Phase III clinical trial for the treatment of head and neck cancer. The Multikine is an immunotherapeutic agent consisting of a mixture of cytokines that produce an anti-tumor immune response. It also develops Ligand Epitope Antigen Presentation System (LEAPs), a heteroconjugate technology that stimulates the human immune system to fight bacterial, viral, and parasitic infections, as well as autoimmune, allergies, transplantation rejection, and cancer. The company, through its LEAPS technology, develops a peptide treatment for H1N1 hospitalized patients; and CEL-2000, a rheumatoid arthritis vaccine. CEL-SCI Corporation was founded in 1983 and is based in Vienna, Virginia.
Medicine Cancer Medical Specialties Immunology Immunotherapy Immune System Rheumatoid Arthritis Vaccination Transplantation Autoimmunity Vaccine Head And Neck Cancer Allergies Treatment Of Head And Neck Cancer
Is CVM a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 2 bullish, 1 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 8.99
52 Week Low 0.82
Average Volume 1,017,738
200-Day Moving Average 4.2879
50-Day Moving Average 6.422
20-Day Moving Average 7.6375
10-Day Moving Average 7.121
Average True Range 0.7353
ADX 27.99
+DI 19.6386
-DI 29.182
Chandelier Exit (Long, 3 ATRs ) 6.7841
Chandelier Exit (Short, 3 ATRs ) 8.0059
Upper Bollinger Band 9.4277
Lower Bollinger Band 5.8473
Percent B (%b) 0.2
BandWidth 46.879214
MACD Line 0.0028
MACD Signal Line 0.2841
MACD Histogram -0.2813
Fundamentals Value
Market Cap 61.32 Million
Num Shares 9.33 Million
EPS -1.54
Price-to-Earnings (P/E) Ratio -4.27
Price-to-Sales 102.40
Price-to-Book 0.00
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 6.95
Resistance 3 (R3) 6.93 6.79 6.88
Resistance 2 (R2) 6.79 6.69 6.80 6.86
Resistance 1 (R1) 6.68 6.64 6.74 6.70 6.84
Pivot Point 6.54 6.54 6.57 6.55 6.54
Support 1 (S1) 6.43 6.44 6.49 6.45 6.30
Support 2 (S2) 6.29 6.39 6.30 6.28
Support 3 (S3) 6.18 6.29 6.26
Support 4 (S4) 6.20